LATEST FROM IPOX^®

News

News and updates from IPOX^®, including media mentions, interviews, research and press releases.

Media mentions · Reuters

Reuters: IPOX^® Analyst Muehlbauer Weighs in on Aeromexico's NYSE Debut Amid Regulatory Challenges

IPOX^® Research Analyst Lukas Muehlbauer commented on Grupo Aeromexico's NYSE debut, where shares opened at $19.16, valuing the airline at $2.8 billion post-bankruptcy. The IPO raised $222.8 million amid regulatory scrutiny over Mexican routes and Delta joint venture. Muehlbauer noted investors are overlooking immediate concerns, buoyed by Aeromexico's recovery and efficient restructuring, though disputes may pressure stock performance until resolved.

November 6, 2025

Media mentions · Webinar

Webinar: Exploring IPO Investment Opportunities – First Trust × IPOX^® Interview (Chinese / 中文)

In this First Trust Webinar, IPOX^® Senior Investment Manager Kat Liu, CFA, delivers essential insights into the US IPO market and why IPO investment is important. She details the First Trust U.S. Equity Opportunities ETF (FPX), which employs systematic screening and a patented "1000 trading days" framework. FPX achieved 12.27% annualized returns since 2006 (as of 9/30/25), outperforming the S&P 500 with nearly 40% year-to-date gains.

November 6, 2025

Media mentions · Bloomberg

Bloomberg: IPOX^® Associate Muehlbauer Highlights MENA IPO Performance

Smaller Saudi firms like Cherry Trading Co. ($67M IPO) and Almasar Alshamil Education Co. ($160M) are testing the subdued equity market, where valuation discipline is key amid investor caution. MENA IPOs raised $5.1B this year, but many trade below offer prices, contrasting global gains. IPOX^® Research Associate Lukas Muehlbauer notes: "Newly listed stocks across the Middle East and North Africa have declined this year... global asset managers expect more disciplined pricing." This signals a fundamentals-driven shift.

November 6, 2025

Media mentions · Reuters

Reuters: IPOX^® VP Kat Liu on Xanadu’s $3.6B SPAC listing

In a Reuters feature on Xanadu Quantum Technologies’ $3.6 billion SPAC merger with Crane Harbor Acquisition Corp., IPOX^® Vice President Kat Liu highlighted the strategic advantages of the SPAC route. Liu noted that such deals provide “a large, single-tranche capital infusion, extending the company’s R&D runway and ensuring survival in a market where venture appetite for capital-intensive quantum projects has cooled.”

November 4, 2025Kat Liu

Media mentions · Bloomberg

Bloomberg: IPOX^® Founder Josef Schuster on the Growing Momentum Behind Industrial Spinoffs

In Bloomberg’s ECM Watch, IPOX^® Founder Josef Schuster commented on the surge in U.S. industrial spinoffs following Honeywell’s and DuPont’s high-profile separations. Schuster noted that “the dynamics these companies are creating are pretty solid,” emphasizing that many recent spin-offs are backed by strong fundamentals. While early trading can see selling pressure, he highlighted that size and index inclusion often support long-term performance.

October 31, 2025Josef Schuster

Media mentions · Reuters

Reuters: IPOX^® Vice President Kat Liu Comments on Navan’s Nasdaq Debut and AI-Driven IPO Market

In a recent Reuters article, IPOX^® VP Kat Liu commented on travel tech firm Navan’s $923 million Nasdaq debut, highlighting the growing investor interest in AI-driven IPOs. Liu noted that, “For Navan to be a true credible AI story, it needs to demonstrate some unique and hard-to-replicate value.” Her remarks underscore IPOX^®’s continued insight into how innovation and authenticity shape success in today’s evolving IPO market.

October 30, 2025Kat Liu

Media mentions · Reuters

Reuters: IPOX^® Analyst Muehlbauer Comments on Medline’s Blockbuster U.S. IPO Filing

Reuters highlights Medline’s blockbuster U.S. IPO filing, which could value the healthcare giant at up to $50 billion. Commenting on the deal, IPOX^® Research Associate Lukas Muehlbauer said the offering “signals that the IPO market remains wide open despite the shutdown” and will serve as a key test of investor confidence heading into 2026. Medline’s listing, expected to be one of the year’s largest, underscores renewed strength in the U.S. IPO market after several years of subdued activity.

October 28, 2025

Media mentions · Reuters

Reuters: IPOX^® Research Associate Lukas Muehlbauer Comments on Biotech IPO Market Amid MapLight’s Nasdaq Debut

Reuters features IPOX^® Research Associate Lukas Muehlbauer commenting on the biotech IPO rebound following MapLight Therapeutics’ $787 million Nasdaq debut. Muehlbauer notes that while the market is “slowly thawing,” many 2021–2023 listings still trade below offer prices, creating challenges for early-stage biotech firms seeking investor confidence.

October 27, 2025Lukas Muehlbauer

Media mentions

Q3 Earnings Season Kicks Off for IPOX^® Index Constituents

Earnings season is in full swing, with U.S. banks kicking off the reporting cycle and key IPOX^® Index constituents set to follow. Next week will feature major updates from leading firms across the IPOX^® 100 U.S. , IPOX^® Europe , and IPOX^® International indexes — including GE Vernova, IBM, Nextracker, MilDef, Porsche, and CATL — offering valuable insight into global sector performance and momentum across IPOX^® portfolios.

October 14, 2025

News

Stay ahead of the next listing.